Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
post-traumatic stress disorder
Biotech
Lykos still plotting path to approval for rejected MDMA therapy
“We continue to chart a path forward for an independent third-party review of prior phase 3 clinical data and an additional trial,” the company said.
James Waldron
Jan 17, 2025 9:00am
Compass shows safety in first psilocybin trial for PTSD
Dec 20, 2023 7:26am
Bionomics' midphase PTSD clinical trial hits primary endpoint
Sep 28, 2023 7:08am
Aptinyx dumps dementia drug, stops PTSD trial after phase 2 flop
Feb 28, 2023 6:15am
